332 related articles for article (PubMed ID: 32464280)
1. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK; Ueno M; Yoo C; Finn RS; Furuse J; Ren Z; Yau T; Klümpen HJ; Chan SL; Ozaka M; Verslype C; Bouattour M; Park JO; Barajas O; Pelzer U; Valle JW; Yu L; Malhotra U; Siegel AB; Edeline J; Vogel A;
Lancet; 2023 Jun; 401(10391):1853-1865. PubMed ID: 37075781
[TBL] [Abstract][Full Text] [Related]
4. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Valle JW; Vogel A; Denlinger CS; He AR; Bai LY; Orlova R; Van Cutsem E; Adeva J; Chen LT; Obermannova R; Ettrich TJ; Chen JS; Wasan H; Girvan AC; Zhang W; Liu J; Tang C; Ebert PJ; Aggarwal A; McNeely SC; Moser BA; Oliveira JM; Carlesi R; Walgren RA; Oh DY
Lancet Oncol; 2021 Oct; 22(10):1468-1482. PubMed ID: 34592180
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
[TBL] [Abstract][Full Text] [Related]
11. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C
BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885
[TBL] [Abstract][Full Text] [Related]
12. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK; Chon HJ; Cheon J; Lee MA; Im HS; Jang JS; Kim MH; Park S; Kang B; Hong M; Kim JW; Park HS; Kang MJ; Park YN; Choi HJ
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
16. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C; Wu L; Fan Y; Wang Z; Liu L; Chen G; Zhang L; Huang D; Cang S; Yang Z; Zhou J; Zhou C; Li B; Li J; Fan M; Cui J; Li Y; Zhao H; Fang J; Xue J; Hu C; Sun P; Du Y; Zhou H; Wang S; Zhang W
J Thorac Oncol; 2021 Sep; 16(9):1501-1511. PubMed ID: 34048947
[TBL] [Abstract][Full Text] [Related]
17. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
18. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
